Drugs

HTA ID	Drug	Brand	Indication	Assessment status	Date
-	Atezolizumab	Tecentriq®	For the treatment of adult patients with locally advanced or metastatic urothelial carcinoma (UC) after prior platinum-containing chemotherapy.	Rapid Review Complete	7th June 2019
-	Atezolizumab	Tecentriq®	As monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic NSCLC after prior chemotherapy. Patients with EGFR activating mutations or ALK‑positive tumour mutations should also have received targeted therapy before receiving atezolizumab.	NCPE Assessment Process Complete	25th September 2018
21012	Atezolizumab	Tecentriq®	As monotherapy for the first-line treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumours have a PD-L1 expression ≥50% tumour cells (TC) or ≥10% tumour-infiltrating immune cells (IC) and who do not have EGFR mutant or ALK-positive NSCLC.	Rapid Review Complete	21st April 2021
22036	Atezolizumab	Tecentriq®	As an adjuvant treatment following complete resection and platinum-based chemotherapy for adult patients with NSCLC with a high risk of recurrence whose tumours have PD-L1 expression on ≥ 50% of tumour cells and who do not have EGFR mutant or ALK-positive NSCLC.	NCPE Assessment Process Complete	15th May 2024
-	Atezolizumab	Tecentriq®	In combination with nab-paclitaxel is indicated for the treatment of adult patients with unresectable locally advanced or metastatic triple-negative breast cancer whose tumours have PD-L1 expression ≥ 1% and who have not received prior chemotherapy for metastatic disease.	NCPE Assessment Process Complete	1st September 2020
19030	Atezolizumab	Tecentriq®	In combination with carboplatin and etoposide is indicated for first-line treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC).	NCPE Assessment Process Complete	24th September 2020
20060	Atezolizumab in combination with bevacizumab	Tecentriq®	For the treatment of adult patients with advanced or unresectable hepatocellular carcinoma who have not received prior systemic therapy.	NCPE Assessment Process Complete	5th June 2024
20039	Atezolizumab	Tecentriq®	Atezolizumab monotherapy is indicated as treatment of locally advanced or metastatic urothelial carcinoma (LaMUC) in adult patients who are considered cisplatin-ineligible and whose tumours have PD-L1 expression ≥5%.	Rapid Review Complete	23rd September 2020
21009	Atidarsagene autotemcel	Libmeldy®	For the treatment of metachromatic leukodystrophy characterized by biallelic mutations in the ARSA gene leading to a reduction of the ARSA enzymatic activity, in children with late infantile or early juvenile forms without clinical manifestations of the disease, and in children with the early juvenile form, with early clinical manifestations of the disease, who still have the ability to walk independently and before the onset of cognitive decline.	NCPE Assessment Process Complete	24th January 2024
23059	Atogepant	Aquipta®	Atogepant is indicated for the prophylaxis of migraine in adults who have at least four migraine days per month.	Rapid Review Complete	26th October 2023
23039	Atogepant	Aquipta®	Prophylaxis of migraine in adults who have at least 4 migraine days per month	Rapid Review Complete	21st August 2023
21005	Autologous anti-CD19-transduced CD3+ cells	Tecartus®	For the treatment of adult patients with relapsed or refractory mantle cell lymphoma after two or more lines of systemic therapy including a Bruton’s tyrosine kinase inhibitor.	Rapid Review Complete	17th July 2023
22009	Avacopan	Tavneos®	In combination with a rituximab or cyclophosphamide regimen, is indicated for the treatment of adult patients with severe, active granulomatosis with polyangiitis or microscopic  polyangiitis.	NCPE Assessment Process Complete	5th June 2024
-	Avanafil	Spedra®	For the treatment of erectile dysfunction in adult men.	Rapid Review Complete	2nd May 2014
20006	Avatrombopag	Doptelet®	For the treatment of severe thrombocytopenia in adult patients with chronic liver disease who are scheduled to undergo an invasive procedure.	Rapid Review Complete	2nd April 2020
20058	Avatrombopag	Doptelet®	For the treatment of primary chronic immune thrombocytopenia (ITP) in adult patients who are refractory to other treatments (e.g. corticosteroids, immunoglobulins).	Rapid Review Complete	15th February 2021
-	Avelumab	Bavencio®	For the treatment of adults with metastatic Merkel Cell Carcinoma.	NCPE Assessment Process Complete	9th October 2018
19046	Avelumab	Bavencio®	Avelumab in combination with axitinib is indicated for the first-line treatment of adult patients with advanced renal cell carcinoma.	NCPE Assessment Process Complete	23rd June 2021
21001	Avelumab	Bavencio®	As monotherapy for the first-line maintenance treatment of adult patients with locally advanced or metastatic urothelial carcinoma whose disease has not progressed with first line platinum-based induction chemotherapy.	NCPE Assessment Process Complete	22nd December 2021
-	Axicabtagene Ciloleucel	Yescarta®	For the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and primary mediastinal large B-cell lymphoma (PMBCL), after two or more lines of systemic therapy.	NCPE Assessment Process Complete	25th February 2020
22066	Axicabtagene ciloleucel	Yescarta®	For the treatment of adult patients with diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL) that relapses within 12 months from completion of, or is refractory to, first-line chemoimmunotherapy.	NCPE Assessment Process complete	16th October 2024
-	Axitinib	Inlyta®	For the treatment of adult patients with advanced renal cell carcinoma (RCC) after failure of prior treatment with sunitinib or a cytokine	Rapid Review Complete	20th November 2012
-	Azelastine hydrochloride and fluticasone propionate (nasal spray)	Dymista®	For symptomatic treatment of moderate-to-severe allergic rhinitis, in patients aged 12 years and older for whom monotherapy with either intranasal antihistamine or glucocorticoid is not considered sufficient.	Rapid Review Complete	28th February 2013
-	Azilsartan	Edarbi®	For the treatment of essential hypertension in adults.	Rapid Review Complete	11th January 2012
24037	Aztreonam-avibactam	Emblaveo®	For the treatment of the following infections in adult patients: • Complicated intra-abdominal infection (cIAI) • Hospital-acquired pneumonia (HAP), including ventilator-associated pneumonia (VAP) • Complicated urinary tract infection (cUTI), including pyelonephritis. Aztreonam-avibactam is also indicated for the treatment of infections due to aerobic Gram-negative organisms in adult patients with limited treatment options.	Rapid Review complete	25th October 2024
21050	Baricitinib	Olumiant®	Treatment of moderate to severe atopic dermatitis in adult patients who are candidates for systemic therapy.	Rapid Review complete	16th December 2021
-	Baricitinib	Olumiant®	Treatment of moderate to severe active rheumatoid arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more disease-modifying anti-rheumatic drugs. Baricitinib may be used as monotherapy or in combination with methotrexate.	Rapid Review complete	13th July 2017
20056	Baricitinib	Olumiant®	Treatment of moderate to severe atopic dermatitis in adult patients who are candidates for systemic therapy.	Rapid Review complete	28th January 2021
-	Bazedoxifene	Conbriza®	Treatment of postmenopausal osteoporosis in women at increased risk of fracture.  A significant reduction in the incidence of verterbral fractures has been demonstrated; efficacy on hip fractures has not been established.	Rapid Review complete	2nd January 2011
23037	Beclometasone /formoterol	Fostair®	Beclometasone / formoterol (Fostair®) for COPD. HTA ID 23037 Symptomatic treatment of patients with severe chronic obstructive pulmonary disease [COPD] (forced expiratory volume [FEV1] <50% predicted normal) and a history of repeated exacerbations, who have significant symptoms despite regular therapy with long-acting bronchodilators.	Rapid Review Complete	20th July 2023
23033	Beclometasone dipropionate anhydrous + formoterol fumarate dihydrate + glycopyrronium bromide	Trimbow®	Beclometasone dipropionate anhydrous + formoterol fumarate dihydrate + glycopyrronium bromide (Trimbow®) is indicated for maintenance treatment in adult patients with moderate to severe chronic obstructive pulmonary disorder (COPD) who are not adequately treated by a combination of an inhaled corticosteroid (ICS) and a long-acting beta2-agonist (LABA) or a combination of a long-acting beta2-agonist (LABA) and a long-acting muscarinic antagonist (LAMA).	Rapid Review Complete	19th July 2023
23034	Beclometasone dipropionate anhydrous + formoterol fumarate dihydrate + glycopyrronium bromide	Trimbow®	Beclometasone dipropionate anhydrous + formoterol fumarate dihydrate + glycopyrronium bromide (Trimbow®) for the maintenance treatment of asthma, in adults not adequately controlled with a maintenance combination of a long-acting beta2-agonist and a medium or high dose of inhaled corticosteroid, and who experienced one or more asthma exacerbations in the previous year	Rapid Review Complete	19th July 2023
23038	Beclometasone/formoterol	Fostair®	Beclometasone/formoterol (Fostair®) is indicated for the regular treatment of asthma where use of a combination product (inhaled corticosteroid [ICS] and long-acting beta2-agonist [LABA]) is appropriate: -in patients not adequately controlled with ICS and 'as needed' inhaled rapid-acting beta2-agonist; or -in patients already adequately controlled on both ICS and LABA.	Rapid Review Complete	20th July 2023
-	Bedaquiline	Sirturo®	For use as part of an appropriate combination regimen for pulmonary MDR‑TB in adult patients when an effective treatment regimen cannot otherwise be composed for reasons of resistance or tolerability. Consideration should be given to official guidance on the appropriate use of antibacterial agents.	Rapid Review complete	20th February 2015
-	Belatacept	Nulojix®	In combination with corticosteroids and a mycophenolic acid (MPA), for prophylaxis of graft rejection in adults receiving a renal transplant. It is recommended to add an interleukin (IL)-2 receptor antagonist for induction therapy to this belatacept-based regimen.	Rapid Review complete	23rd January 2012
-	Belimumab	Benlysta®	As add-on therapy in adult patients with active, autoantibody-positive systemic lupus erythematosus (SLE) with a high degree of disease activity (e.g., positive anti-dsDNA and low complement) despite standard therapy.	Rapid Review complete	31st August 2011
23021	Belimumab	Benlysta®	Belimumab is indicated in combination with background immunosuppressive therapies for the treatment of adult patients with active lupus nephritis.	Rapid Review Complete	16th May 2023
23022	Belimumab	Benlysta®	Belimumab is indicated as add-on therapy in patients aged five years and older with active, autoantibody-positive systemic lupus erythematosus with a high degree of disease activity (e.g., positive anti-dsDNA and low complement) despite standard therapy.	Rapid Review Complete	29th May 2023
20026a	Bempedoic acid	Nilemdo®	In adults with primary hypercholesterolaemia (heterozygous familial and non-familial) or mixed dyslipidemia, as an adjunct to diet: In combination with a statin or statin with other lipid-lowering therapies in patients unable to reach LDL-C goals with the maximum tolerated dose of a statin, OR Alone or in combination with other lipid-lowering therapies in patients who are statin-intolerant, or for whom a statin is contraindicated	NCPE Assessment process complete	16th November 2021
20026b	Bempedoic acid/Ezetimibe	Nustendi®	In adults with primary hypercholesterolaemia (heterozygous familial and non-familial) or mixed dyslipidaemia, as an adjunct to diet (a) in combination with a statin in patients unable to reach LDL-C goals with the maximum tolerated dose of a statin in addition to ezetimibe (b) alone in patients who are either statin – intolerant or for whom a statin is contraindicated and are unable to reach LDL-C goals with ezetimibe alone and (c) in patients already being treated with the combination of bempedoic acid and ezetimibe as separate tablets with or without a statin.	NCPE Assessment Process Complete	16th November 2021
-	Bendamustine	Levact®	Treatment of Chronic Lymphocytic Leukaemia (CLL)	NCPE Assessment Process Complete	20th November 2012
-	Benralizumab	Fasenra®	As add-on maintenance treatment in adult patients with severe eosinophilic asthma inadequately controlled despite high-dose inhaled corticosteroids plus long-acting β-agonists.	Rapid Review complete	14th February 2018
20018	Benralizumab	Fasenra®	As an add-on maintenance treatment in adult patients with severe eosinophilic asthma inadequately controlled despite high-dose inhaled corticosteroids plus long-acting β-agonists.	Rapid Review complete	28th April 2020
22031	Berotralstat	Orladeyo®	Routine prevention of recurrent attacks of hereditary angioedema in adult and adolescent patients aged 12 years and older	Rapid Review Complete	28th March 2023
-	Bezlotoxumab	Zinplava®	Prevention of recurrence of Clostridium difficile infection (CDI) in adults at high risk for recurrence of CDI.	Rapid Review complete	14th June 2017
-	Bictegravir/emtricitabine/tenofovir alafenamide	Biktarvy®	Treatment of adults infected with HIV-1 without any known mutations associated with resistance to the individual components.	Rapid Review complete	7th June 2018
-	Bilastine	Drynol®	Symptomatic treatment of allergic rhino-conjunctivitis (seasonal and perennial) and urticaria.	Rapid Review complete	23rd March 2011
23075	Bimekizumab	Bimzelx®	Bimekizumab (Bimzelx®) is indicated alone or in combination with methotrexate, for the treatment of active psoriatic arthritis in adults who have had an inadequate response or who have been intolerant to one or more disease-modifying antirheumatic drugs	Rapid Review Complete	5th June 2024
21052	Bimekizumab	Bimzelx®	Treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy.	Rapid Review complete	6th July 2023
23069	Birch bark extract	Filsuvez®	Treatment of partial thickness wounds associated with dystrophic and junctional epidermolysis bullosa (EB) in patients 6 months and older.	Full HTA submission received from Applicant	15th October 2024